|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
BiPar Sciences, Inc. Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs
9/10/2009 8:59:39 AM
SAN FRANCISCO, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Tom White, cofounder and former chief executive officer (CEO) of BiPar Sciences, the successful biotech firm recently acquired by Sanofi-Aventis for $500 million, announced today that G. Kirk Raab and John Schembri have joined TriAct Therapeutics, a clinical-stage biopharmaceutical company developing novel signaling pathway inhibitors to address the significant unmet needs of lung cancer patients. White co-founded TriAct with a group from UCSF, and serves as its president and CEO. Raab and Schembri will serve in the Chairman and Chief Financial Officer (CFO) roles, respectively, at TriAct. The company is also searching for senior clinical and regulatory personnel to fill out its team.
|
|
|
|
|
|
|
|
|
|
|